Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma by unknown
Li et al. Diagnostic Pathology 2014, 9:226
http://www.diagnosticpathology.org/content/9/1/226RESEARCH Open AccessUpregulation of microRNA-106b is associated
with poor prognosis in hepatocellular carcinoma
Bin-Kui Li1,2, Pin-Zhu Huang1,2, Ji-Liang Qiu1,2, Ya-Di Liao1,2, Jian Hong1,2 and Yun-Fei Yuan1,2*Abstract
Background: MicroRNA-106b (miR-106b) is a member of the miR-106b ~ 25 cluster. It has been reported that
miR-106b acts as an oncogene and is upregulated in many human cancers. However, the prognostic value of
miR-106b in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to investigate the clinical
significance of miR-106b expression in HCC.
Methods: We determined the expression level of miR-106b in 104 cases of paired HCC and adjacent non-tumor
tissues by quantitative real-time PCR (qRT-PCR). The correlation between miR-106b expression and prognosis of
HCC was studied by univariate and multivariate analysis. Multivariate analysis of the prognostic factors was
performed with Cox proportional hazards model.
Results: MiR-106b expression was significantly upregulated in as high as 76.0% of HCC tissues, compared with their
non-tumor counterparts (P < 0.001). High miR-106b expression was significantly associated with large tumor size
(P = 0.019) and vascular invasion (P = 0.016). Kaplan-Meier analysis showed that patients with high miR-106b
expression had a worse overall survival than patients with low miR-106b expression (log-rank P = 0.004). The
multivariate Cox regression analysis indicated that miR-106b expression was an independent prognostic factor for
overall survival (HR, 2.002; 95% CI, 1.130-6.977; P = 0.027).
Conclusion: Our data indicated that miR-106b expression was significantly upregulated in HCC and could serve as
a potential unfavorable prognostic biomarker.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_226
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Hepatocellular carcinoma (HCC) is one of the most
common cancers worldwide with poor prognosis [1]. Ac-
curate prediction of prognosis and patient stratification
are crucial for guiding patients’ personalized clinical
treatment. These are currently performed by clinical
and/or pathological staging systems [2-4]. Recently im-
portant progress has been made with using comprehen-
sive approaches to identify the molecular diversity in
HCC. A large number of genetic and epigenetic ab-
normalities were found during the process of HCC de-
velopment [5-8]. Consequently, many new prognostic* Correspondence: yuanyf@mail.sysu.edu.cn
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unless otherwise stated.biomarkers of HCC have been described [9,10]. Addition
of new biomarkers in the current staging systems is
likely to improve the prognostic prediction of HCC pa-
tients and identify specific subgroups of tumor.
MicroRNAs (miRNAs) are highly conserved, small
non-coding RNA molecules of approximately 22 nucleo-
tides in length that function as posttranscriptional gene
regulators [11,12]. Many studies have shown that miR-
NAs are directly involved in cancer initiation and pro-
gression. Indeed, miRNAs could act as oncogenes or
tumor suppressors [13,14]. In addition, some miRNA de-
regulations were found to be associated with specific
tumor phenotype [15]. These observations suggest that
miRNA could be used as putative biomarkers to classify
tumors.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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which consists of miR-106b, miR-93 and miR-25, that
is encoded within intron 13 of the minichromosome
maintenance complex component 7 (MCM7) gene on
chromosome 7q22.1 [16]. MiR-106b has been reported
as an oncogene and upregulated in many human can-
cers, including stomach, prostate and kidney [17-19].
Previous studies suggest that miR-106b also plays an
important role in hepatocarcinogenesis [20-22]. In our
previous study, using miRNA array, we also found miR-
106b is one of the upregulated miRNAs in HCC [23].
However, the prognostic value of miR-106b in HCC has
not been fully clarified yet.
In the present study, we investigated the expression
levels of miR-106b in resected HCC specimens and adja-
cent non-tumor tissues. We also analyzed the associ-
ation of miR-106b expression with clinicopathological
characteristics and overall survival of the patients and
determined whether miR-106b is potentially predictive
of prognosis in HCC.
Methods
Patients and tissue samples
A total of 104 pairs of tumor and matched adjacent
non-tumor liver tissues were collected from patients
with HCC who underwent hepatic resections between
July 2003 and July 2007 at Sun Yat-sen University
Cancer Center. These patients were selected for hepatic
resection in accordance with our defined criteria [24].
For all cases, tissue samples were obtained immediately
after resection and were snap-frozen in liquid nitrogen
and stored at −80°C until use. All tissues were archived
in the institution’s liver tumor bank. The diagnosis was
confirmed histologically in all cases, based on detailed
examination of sections stained with H&E. None of the
patients had received any other therapy, including per-
cutaneous ablation and chemo-embolization, before
surgery. The research protocol was approved by the
Institutional Review Board of Sun Yat-sen University
Cancer Center. Written informed consent was obtained
from every patient to participate in this study.
Follow-up
Clinical follow-up was performed for all the patients.
All patients were monitored by physical examination,
serum alpha-fetoprotein (AFP), ultrasonography, and x-
ray every 1–3 months in the first year, and every 3–6
months thereafter for surveillance of recurrence or me-
tastases. Computed tomography and/or magnetic reson-
ance imaging and/or positron emission tomography
were used whenever needed to confirm the clinical
findings. The clinical end point in the present study was
overall survival. Overall survival was defined as the
interval from curative surgery to the date of death or thedate of last contact if the patient was still alive. Survival
information of all patients was updated by telephone
visit and questionnaire letters.
Quantitative real-time RT-PCR (qRT-PCR)
To detect miRNA expression by qRT-PCR, total RNA was
extracted from tissue samples using the Trizol reagent
(Invitrogen, Carlsbad, CA, USA). qRT-PCR of miR-106b
was performed using Bulge-Loop™ miRNA qRT-PCR
kits (Ribobio, Guangzhou, China) according to the man-
ufacturer’s instructions. Briefly, reverse transcription
was performed using a specific miR-106b stem-loop pri-
mer and the reverse primer for U6 small nuclear RNA,
followed by real-time PCR with a miR-106b-specific for-
ward primer and a universal reverse primer using an
ABI-Prism 7900HT system (Applied Biosystems, Foster
City, CA). All samples were carried out in triplicate. U6
was used as an endogenous control. The expression
level of miR-106b for each sample was calculated, repre-
sented by the ΔCt value (Ct of miR-106b - Ct of U6). The
relative miR-106b expression levels in paired tissues that
were collected from the same patients were analyzed by
the 2-ΔΔCt method, represented by the -ΔΔCt value
[−(ΔCt of tumor tissues - ΔCt of non-tumor tissues)].
The -ΔΔCt value represents the value of log2 T/NT for
each patient.
Statistical analysis
Statistical comparisons were performed using either the
Student’s t-test, chi-square test or Fisher’s exact test, as
appropriate. In a univariate analysis, survival curves were
assessed by the Kaplan-Meier method, and differences
between curves were analyzed using the log-rank test.
Covariates with P values < 0.05 in the univariate analysis
were subjected to multivariate analysis. Multivariate Cox
regression models were constructed to estimate the hazard
ratios (HRs) of independent factors for survival after con-
trolling for potential confounding factors. All statistical
analyses were carried out using the SPSS (Statistical
Package for the Social Sciences) 13.0 software (SPSS,
Chicago, IL) and GraphPad Prism 5.0 software (Graph-
Pad Software, San Diego, CA). Two-tailed P values <
0.05 were considered statistically significant.
Results
MiR-106b expression in HCC
We performed quantitative real-time RT-PCR to exam-
ine the miR-106b expression level in 104 pairs of HCC
and adjacent non-tumor tissues. As shown in Figure 1,
the expression level of miR-106b in HCC tissues was sig-
nificantly higher than that in adjacent non-tumor tissues
after normalization (median fold change of T/NT = 2.27,
P < 0.001). MiR-106b was upregulated in 79 of 104 pa-
tients (76.0%) totally (Figure 2). The median fold change
Figure 1 Comparison of miR-106b expression levels between HCC tissues and adjacent non-tumor tissues. Analysis using the Student’s
t-test showed that the relative expression levels of miR-106b in the HCC tissues were significantly higher than those in adjacent non-tumor tissues
(P < 0.001). qRT-PCR data are ratios to average of non-tumor tissues.
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104 patients into two groups: the low expression group
(n = 52) and the high expression group (n = 52).
Correlation of miR-106b expression with clinicopathological
characteristics of HCC patients
We next analyzed the correlation between miR-106b
expression and the clinicopathological characteristics of
HCC, including patients’ age, gender, HBsAg, Child-Pugh
classification, serum AFP level, tumor size, tumor number,Figure 2 Upregulation of miR-106b was observed in 79/104
(76.0%) HCCs.vascular invasion, histological grade (Edmondson-Steiner)
and TNM stage. As summarized in Table 1, miR-106b
expression was significantly higher in HCC patients with
large tumor than those with small tumor (P = 0.019).
Additionally, a Pearson correlation analysis also showed
that the miR-106b level and tumor size were positively
correlated (r = 0.2894, P = 0.0029; Figure 3). Moreover,
miR-106b was expressed at significantly higher levels in
patients with vascular invasion than in patients without
vascular invasion (P = 0.016). However, no significant
correlation was observed between miR-106b expression
and other clinicopathological characteristics.
Prognostic analysis of miR-106b expression and
clinicopathological factors
The association between miR-106b expression and prog-
nosis of HCC patients was investigated by Kaplan-Meier
analysis and log-rank test. As shown in Figure 4, HCC
patients with high miR-106b expression had shorter
overall survival than those with low miR-106b expression.
The 1, 3, and 5-year overall survival rate in the high ex-
pression group was 84.0%, 51.6%, and 36.5%, respectively,
compared with 84.4%, 60.2%, and 56.2%, respectively, in
the low expression group (log-rank test, P = 0.004).
Univariate analysis demonstrated that Serum AFP level
(P = 0.041), tumor size (P < 0.001), vascular invasion
Table 1 Correlation between relative miR-106b
expression and clinicopathological characteristics in
HCCs (n = 104)
Characteristics No. of cases miR-106b P valuea
Low High
Age (years)
<50b 49 22 (44.9) 27 (55.1) 0.326
≥50 55 30 (54.5) 25 (45.5)
Gender
Female 10 3 (30.0) 7 (70.0) 0.183
Male 94 49 (52.1) 45 (47.9)
HBsAg
Negative 18 12 (66.7) 6 (33.3) 0.120
Positive 86 40 (46.5) 46 (53.5)
Child-Pugh
A 95 48 (50.5) 47 (49.5) >0.999
B 9 4 (44.4) 5 (55.6)
AFP (μg/L)
<200c 52 30 (57.7) 22 (42.3) 0.117
≥200 52 22 (42.3) 30 (57.7)
Tumor size (cm)
<7d 50 31 (62.0) 19 (38.0) 0.019
≥7 54 21 (38.9) 33 (61.1)
Tumor number
Solitary 70 33 (47.1) 37 (52.9) 0.403
Multiple 34 19 (55.9) 15 (44.1)
Vascular invasion
Absent 82 46 (56.1) 36 (43.9) 0.016
Present 22 6 (27.3) 16 (72.7)
Edmondson-Steiner
I-II 60 34 (56.7) 26 (43.3) 0.112
III-IV 44 18 (40.9) 26 (59.1)
TNM stage
I 51 27 (52.9) 24 (47.1) 0.556
II-III 53 25 (47.2) 28 (52.8)
aChi-square or Fisher’s exact test.
b,c,dValues are median.
Values in parentheses indicate percentage.
Statisticaly significant values are given in bold.
Figure 3 MiR-106b expression correlated with tumor size.
A Pearson correlation analysis showed that the miR-106b level and
tumor size were positively correlated (r = 0.2894, P = 0.0029).
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stage (P = 0.004), and miR-106b expression (P = 0.004)
were significantly associated with overall survival of
HCC patients (Table 2). No significant associations were
found for age at diagnosis, gender, HBsAg status, Child-
Pugh classification, and tumor number. Multivariate
analysis using the Cox proportional hazards model for
variables that were significant in the univariate analysis
showed that tumor size (P = 0.022), vascular invasion(P = 0.028) and miR-106b expression (P = 0.027) were
independent prognostic factors for patients with HCC
(Table 2).
Discussion and conclusions
MiRNAs are considered to be ideal biomarkers for the
diagnosis and prognosis of cancer because they are easy
to detect and strongly associated with clinical prognoses
[25-27]. So far, increasing evidence shows that more and
more deregulated miRNAs are involved in HCC carcino-
genesis and patient prognosis [7,8,20-23,28]. However,
due to the complicated and diverse roles of miRNAs in
HCC, clarifying the clinical significance and function of an
individual miRNA may enable deeper insights into the
complexity of HCC progression and disease management.
MiR-106b is a member of the oncogenic miR-106b-25
cluster [16]. The biological function of miR-106b in HCC
has been investigated in previous studies. It has been
demonstrated that ectopic expression of miR-106b can
enhance the proliferation and anchorage-independent
growth of HCC cells, whereas inhibition of miR-106b
had the opposite effect [20,22]. It has also been shown
that miR-106b contributed to metastasis by activating
the EMT process and promoting cell migration in vitro
and metastasis in vivo in HCC, indicating that upregula-
tion of miR-106b may correlate with HCC progression
[21]. However, the clinical significance and prognostic
value of miR-106b in HCC remain unclear.
In the present study, we analyzed the clinical relevance
of miR-106b expression in HCC patients. Our qRT-PCR
data confirmed that miR-106b expression was upregu-
lated in tumor tissues compared with the adjacent non-
tumor tissues, which validated our previous microarray
high-throughput profiling results [23]. These results are
also consistent with previous findings in other studies
[20,21]. In addition, we correlated clinicopathological
Figure 4 Survival analysis of 104 HCC patients by Kaplan-Meier method. Overall survival rate in patients with high miR-106b expression was
significantly lower than that in patients with low miR-106b expression (log-rank P = 0.004).
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and observed that overexpression of miR-106b correlated
with large tumor size and vascular invasion, which strongly
indicated that this miRNA plays oncogenic roles in HCC,
including promoting cell growth, cell invasion and tumor
metastasis.These observations could be attributed to the
miR-106b target genes, which include p21/CDKN1A, ad-
enomatous polyposis coli (APC), transforming growth
factor-β type II receptor (TGF-βRII), and RhoA and
RhoC [16,21,22,29]. Hence, by regulating its target genes,
miR-106b could promote HCC cell cycle progression, cell
proliferation, and cell migration and invasion.Table 2 Univariate and multivariate Cox regression analyses f
Variable Univariate analysis
HR (95% CI)
miR-106b (high versus low) 2.445 (1.299-4.605)
Age (≥50 versus <50 years) 1.295 (0.691-2.426)
Gender (M versus F) 1.195 (0.368-3.874)
HBsAg (positive versus negative) 1.980 (0.774-5.066)
Child-Pugh (B versus A) 2.027 (0.790-5.199)
AFP (≥200 versus <200 μg/L) 1.926 (1.027-3.612)
Tumor size (≥7 cm versus <7 cm) 3.435 (1.746-6.757)
Tumor number (multiple versus solitary) 1.745 (0.941-3.235)
Vascular invasion (present versus absent) 2.927 (2.083-7.403)
Edmondson-Steiner (III-IV versus I-II) 2.219 (1.006-4.895)
TNM stage (II-III versus I) 2.331 (1.391-5.359)
Statisticaly significant values are given in bold.More importantly, we demonstrated that miR-106b ex-
pression was significantly associated with overall survival
of patients with HCC. Kaplan-Meier analysis showed
that patients with high miR-106b expression level had a
significantly shorter overall survival than those with low
miR-106b expression level. Furthermore, multivariate
Cox analysis proved that miR-106b was a prognostic
factor independent of adjusted well-known prognostic
variables for HCC including serum AFP level, tumor
size, vascular invasion, histological grade, and TNM
stage. Thus, miR-106b could be used as a potential prog-
nostic biomarker in addition to other known prognosticor overall survival
Multivariate analysis
P HR (95% CI) P





0.041 1.263 (0.650-2.453) 0.491
<0.001 2.353 (1.133-4.884) 0.022
0.077 - -
0.001 2.340 (1.001-5.466) 0.028
0.048 1.303 (0.534-3.180) 0.369
0.004 1.234(0.398-3.822) 0.716
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have higher risk of death, thus, should receive monitor-
ing more frequently and effective adjuvant treatment.
Many studies have shown that miRNA profiles are main-
tained and are not significantly affected in formalin-fixed
paraffin-embedded tissues [30,31]. Therefore, although
our study is based on frozen tissue samples, it offers a
significant opportunity for using archived samples to de-
tect changes in miR-106b expression levels by using in
situ hybridization methodology with miRNA localization
in routine clinical setting [32]. In summary, our data in-
dicated that miR-106b expression was significantly up-
regulated and associated with poor prognosis in HCC.
MiR-106b was identified as an independent biomarker
for predicting the clinical prognosis of HCC patients.
Further studies are needed to validate the prognostic
value of miR-106b expression in other cohorts.
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